Choose Your Country or Region

TLR

Choose Selective TLR Inhibitors

Isoform-selective Inhibitors

TLR Products

All (35)
TLR Inhibitors (16)
TLR Antibodies (2)
TLR Activator (1)
TLR Antagonists (4)
TLR Agonists (10)
TLR Modulators (2)
New TLR Products

Catalog No.	Product Name	Information	Product Use Citations
E1134^New	ABR-238901	ABR-238901 is a novel S100A8/A9 blocker that potently inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4).
E3193^New	Saponaria Officinalis Extract	Saponaria Officinalis Extract is extracted from Saponaria Officinalis, which reduces downstream inflammatory responses by disrupting the TLR4/MD2 complex and blocking MyD88-dependent inflammatory signaling.
S0139	MD2-TLR4-IN-1	MD2-TLR4-IN-1 (Compound 22m) is a potent inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4). MD2-TLR4-IN-1 (compound 22m) inhibits lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively.
S0716	E6446	E6446 is an inhibitor of Toll-like receptor (TLR) 7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro.
S3924	Ginsenoside Rb1	Ginsenoside Rb1 (Gypenoside Ⅲ) is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-obesity actions. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65. Ginsenoside Rb1 reduces the expressions of TLR3, TLR4 and TRAF-6, and down-regulates the levels of TNF-α, IFN-β and iNOS.	J Biol Chem, 2021, S0021-9258(21)00790-0 Mol Immunol, 2021, 139:140-152 J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S4157	Chloroquine diphosphate	Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).	Bioact Mater, 2022, 18:459-470 Front Immunol, 2022, 13:853194 Front Oncol, 2022, 12:782877
S4430	Hydroxychloroquine Sulfate (NSC 4375)	Hydroxychloroquine Sulfate (NSC 4375, HCQ) is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9.	J Clin Invest, 2022, e153619 Cell Rep, 2022, 39(3):110712 Cell Death Dis, 2022, 13(3):197
S6573	MD2-IN-1	MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD value of 189 μM.	Br J Pharmacol, 2021, 10.1111/bph.15412
S6597	TLR2-IN-C29	TLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.	Nat Commun, 2022, 13(1):3321 Int J Biol Macromol, 2021, 183:145-157
S6719	E6446 dihydrochloride	E6446 dihydrochloride is a specific Toll-like receptor 9 inhibitor.
S6934	AMG-9810	AMG-9810 is potent, competitive and selective vanilloid receptor 1 (TRPV1) antagonist and inhibits capsaicin activation with IC50 of 24.5 nM and 85.6 nM for human TRPV1 and rat TRPV1, repectively. AMG-9810 blocks all known modes of TRPV1 activation, including protons-, heat-, and endogenous ligands, such as anandamide, N-arachidonyl dopamine, and oleoyldopamine. AMG-9810 significantly reduces the mRNA expression of TLR2 and TLR4. AMG-9810 also promotes mouse skin tumorigenesis mediated through EGFR/Akt/mTOR signaling.
S6999	Chloroquine (NSC-187208)	Chloroquine (NSC-187208, Aralen, CHQ, CQ) is an antimalarial drug and autophagy/lysosome inhibitor. Chloroquine also suppresses Toll-like receptor-9 (TLR9) protein expression. Chloroquine is highly effective agianst SARS-CoV-2 (COVID-19) infection with EC50 of 1.13 μM in Vero E6 cells. Chloroquine has anti-HIV-1 activity.	Bioact Mater, 2022, 18:459-470 Redox Biol, 2022, 52:102292 Cell Death Dis, 2022, 13(2):150
S7455	Resatorvid (TAK-242)	Resatorvid (TAK-242, CLI-095) is a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, blocking LPS-induced production of NO, TNF-α and IL-6 in macrophages with IC50 of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy.	Nat Commun, 2022, 13(1):3321 Gut Microbes, 2022, 14(1):2091369 Cell Death Dis, 2022, 13(4):333
S8562	IRAK4-IN-2	IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades.	Cancer Lett, 2021, 503:75-90 Cancer Lett, 2021, 503:75-90
S8677	Cu-CPT22	CU-CPT22 shows dose-dependent inhibitory effects blocking Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 ± 0.09 µM while no significant inhibition to TLR2/6. It demonstrates minimal non-specific inhibition against a panel of 10 representative kinases (PDGFRB, MET, DDR2, SRC, MAPK1, PAK1, AKT1, PKC-γ, CAMK1, and PLK4).	iScience, 2021, 24(5):102483 Int Immunopharmacol, 2020, 79:106085 Research Square, 2020, 10.21203/rs.3.rs-126752/v1
S9234	Schaftoside	Schaftoside, a bioactive compound found in the Herba Desmodii Styracifolii, exhibits pancreatic lipase inhibitory activity. Schaftoside inhibits the expression of TLR4 and Myd88. Schaftoside also decreases Drp1 expression and phosphorylation, and reduces mitochondrial fission.
A5022	TLR5 Rabbit Recombinant mAb	TLR5 Rabbit Recombinant mAb detects endogenous levels of total TLR5.
A5027	TLR9 Rabbit Recombinant mAb	TLR9 Rabbit Recombinant mAb detects endogenous levels of total TLR9.
S9937^New	CU-CPD107	CU-CPD107 is a selective, dual-activity small-molecule which demonstrated differential activity against the TLR8 agonists and ssRNA ligands. In the presence of R848, CU-CPD107 acts as a TLR8 signaling inhibitor (IC50=13.7 μM). In the presence of ssRNA, CU-CPD107 shows synergistic agonist activities, while CU-CPD107 alone is unable to influence TLR8 signaling.
S0002	IAXO-102	IAXO-102 is an antagonist of TLR4 targeting both MD-2 and CD14 co-receptors. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and downregulates the expression of TLR4 dependent proinflammatory proteins. IAXO-102 inhibits experimental abdominal aortic aneurysm (AAA) development.
S0822	TLR4-IN-C34	TLR4-IN-C34 (TLR4-C34, C34, TLR4-C34-IN) is a potent and selective antagonist of Toll-like receptor 4 (TLR4). TLR4-IN-C34 reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.	Sci Total Environ, 2022, 838(Pt 2):155825
S4461	CU-CPT-8m	CU-CPT-8m (CPD1578) is a specific antagonist of toll-like receptor 8(TLR8) with IC50 of 67 nM and Kd of 220 nM.
S9730	CU-CPT9a	CU-CPT9a is a potent and specific antagonist of Toll-like receptor 8 (TLR8) with IC50 of 0.5 nM.
E0639^New	TLR7/8 agonist 1 dihydrochloride	TLR7/8 agonist 1 dihydrochloride is a toll-like receptor TLR7/TLR8 dual-agonistic imidazoquinoline.TLR7/8 agonist 1 retains TLR7-agonistic activity with an EC50 of 20 nM.
S0078	1V209 (TLR7 agonist T7)	1V209 (T7, TLR7 agonist T7) is an agonist of Toll-like receptor 7 (TLR7) with anti-tumor effects. 1V209 can be used as vaccine adjuvants, enhances antigen specific humoral and cellular immune responses.
S0494	SM 324405	SM 324405 (compound 9e) is a potent and selective Toll-like receptor 7 (TLR7) agonist with EC50 of 50 nM.
S2952	SM-276001	SM-276001 is a potent and selective agonist of TLR7 that induces antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.
S2979	CU-T12-9	CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.
S7161	Motolimod (VTX-2337)	Motolimod (VTX-2337) is a selective and potent Toll-like receptor 8 (TLR8) agonist with EC50 of 100 nM, > 50-fold selectivity over TLR7. Phase 2.	Cell Rep, 2021, 35(7):109143 J Leukoc Biol, 2020, 1 J Pharm Biomed Anal, 2020, 179:112987
S7221	Vesatolimod (GS-9620)	Vesatolimod (GS-9620) is a potent and selective orally active small molecule agonist of Toll-like receptor 7.	PLoS Pathog, 2022, 18(3):e1010354 J Pharm Biomed Anal, 2020, 179:112987 Stem Cell Res Ther, 2019, 10(1):387
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.	Small, 2022, 18(4):e2103552 Adv Mater, 2021, 33(51):e2104362 Pharmaceutics, 2021, 13(3)365
S8428^New	FSL-1	FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection.
S9623	Telratolimod	Telratolimod (3M-052, MEDI9197) is an agonist of toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) with antitumor activity.
E3594^New	Radix tetrastigme Extract	Radix Tetrastigme Extract is extracted from Tetrastigma hemsleyanum, which can modulate TLR4/COX-2/NF-κB signaling pathway.
E3625^New	Cnidii Fructus Extract	Cnidii Fructus Extract is extracted from Cnidii Fructus, the dry ripe fruit of Cnidium monnieri (L.)Cuss.. Chinese herbal medicine Cnidii Fructus has an outstanding effect on chronic lumbar pain and impotence, also has been used against osteoporosis with high frequency.
E1134^New	ABR-238901	ABR-238901 is a novel S100A8/A9 blocker that potently inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4).
E3193^New	Saponaria Officinalis Extract	Saponaria Officinalis Extract is extracted from Saponaria Officinalis, which reduces downstream inflammatory responses by disrupting the TLR4/MD2 complex and blocking MyD88-dependent inflammatory signaling.
S0139	MD2-TLR4-IN-1	MD2-TLR4-IN-1 (Compound 22m) is a potent inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4). MD2-TLR4-IN-1 (compound 22m) inhibits lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively.
S0716	E6446	E6446 is an inhibitor of Toll-like receptor (TLR) 7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro.
S3924	Ginsenoside Rb1	Ginsenoside Rb1 (Gypenoside Ⅲ) is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-obesity actions. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65. Ginsenoside Rb1 reduces the expressions of TLR3, TLR4 and TRAF-6, and down-regulates the levels of TNF-α, IFN-β and iNOS.	J Biol Chem, 2021, S0021-9258(21)00790-0 Mol Immunol, 2021, 139:140-152 J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S4157	Chloroquine diphosphate	Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).	Bioact Mater, 2022, 18:459-470 Front Immunol, 2022, 13:853194 Front Oncol, 2022, 12:782877
S4430	Hydroxychloroquine Sulfate (NSC 4375)	Hydroxychloroquine Sulfate (NSC 4375, HCQ) is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9.	J Clin Invest, 2022, e153619 Cell Rep, 2022, 39(3):110712 Cell Death Dis, 2022, 13(3):197
S6573	MD2-IN-1	MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD value of 189 μM.	Br J Pharmacol, 2021, 10.1111/bph.15412
S6597	TLR2-IN-C29	TLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.	Nat Commun, 2022, 13(1):3321 Int J Biol Macromol, 2021, 183:145-157
S6719	E6446 dihydrochloride	E6446 dihydrochloride is a specific Toll-like receptor 9 inhibitor.
S6934	AMG-9810	AMG-9810 is potent, competitive and selective vanilloid receptor 1 (TRPV1) antagonist and inhibits capsaicin activation with IC50 of 24.5 nM and 85.6 nM for human TRPV1 and rat TRPV1, repectively. AMG-9810 blocks all known modes of TRPV1 activation, including protons-, heat-, and endogenous ligands, such as anandamide, N-arachidonyl dopamine, and oleoyldopamine. AMG-9810 significantly reduces the mRNA expression of TLR2 and TLR4. AMG-9810 also promotes mouse skin tumorigenesis mediated through EGFR/Akt/mTOR signaling.
S6999	Chloroquine (NSC-187208)	Chloroquine (NSC-187208, Aralen, CHQ, CQ) is an antimalarial drug and autophagy/lysosome inhibitor. Chloroquine also suppresses Toll-like receptor-9 (TLR9) protein expression. Chloroquine is highly effective agianst SARS-CoV-2 (COVID-19) infection with EC50 of 1.13 μM in Vero E6 cells. Chloroquine has anti-HIV-1 activity.	Bioact Mater, 2022, 18:459-470 Redox Biol, 2022, 52:102292 Cell Death Dis, 2022, 13(2):150
S7455	Resatorvid (TAK-242)	Resatorvid (TAK-242, CLI-095) is a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, blocking LPS-induced production of NO, TNF-α and IL-6 in macrophages with IC50 of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy.	Nat Commun, 2022, 13(1):3321 Gut Microbes, 2022, 14(1):2091369 Cell Death Dis, 2022, 13(4):333
S8562	IRAK4-IN-2	IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades.	Cancer Lett, 2021, 503:75-90 Cancer Lett, 2021, 503:75-90
S8677	Cu-CPT22	CU-CPT22 shows dose-dependent inhibitory effects blocking Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 ± 0.09 µM while no significant inhibition to TLR2/6. It demonstrates minimal non-specific inhibition against a panel of 10 representative kinases (PDGFRB, MET, DDR2, SRC, MAPK1, PAK1, AKT1, PKC-γ, CAMK1, and PLK4).	iScience, 2021, 24(5):102483 Int Immunopharmacol, 2020, 79:106085 Research Square, 2020, 10.21203/rs.3.rs-126752/v1
S9234	Schaftoside	Schaftoside, a bioactive compound found in the Herba Desmodii Styracifolii, exhibits pancreatic lipase inhibitory activity. Schaftoside inhibits the expression of TLR4 and Myd88. Schaftoside also decreases Drp1 expression and phosphorylation, and reduces mitochondrial fission.
A5022	TLR5 Rabbit Recombinant mAb	TLR5 Rabbit Recombinant mAb detects endogenous levels of total TLR5.
A5027	TLR9 Rabbit Recombinant mAb	TLR9 Rabbit Recombinant mAb detects endogenous levels of total TLR9.
S9937^New	CU-CPD107	CU-CPD107 is a selective, dual-activity small-molecule which demonstrated differential activity against the TLR8 agonists and ssRNA ligands. In the presence of R848, CU-CPD107 acts as a TLR8 signaling inhibitor (IC50=13.7 μM). In the presence of ssRNA, CU-CPD107 shows synergistic agonist activities, while CU-CPD107 alone is unable to influence TLR8 signaling.
S0002	IAXO-102	IAXO-102 is an antagonist of TLR4 targeting both MD-2 and CD14 co-receptors. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and downregulates the expression of TLR4 dependent proinflammatory proteins. IAXO-102 inhibits experimental abdominal aortic aneurysm (AAA) development.
S0822	TLR4-IN-C34	TLR4-IN-C34 (TLR4-C34, C34, TLR4-C34-IN) is a potent and selective antagonist of Toll-like receptor 4 (TLR4). TLR4-IN-C34 reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.	Sci Total Environ, 2022, 838(Pt 2):155825
S4461	CU-CPT-8m	CU-CPT-8m (CPD1578) is a specific antagonist of toll-like receptor 8(TLR8) with IC50 of 67 nM and Kd of 220 nM.
S9730	CU-CPT9a	CU-CPT9a is a potent and specific antagonist of Toll-like receptor 8 (TLR8) with IC50 of 0.5 nM.
E0639^New	TLR7/8 agonist 1 dihydrochloride	TLR7/8 agonist 1 dihydrochloride is a toll-like receptor TLR7/TLR8 dual-agonistic imidazoquinoline.TLR7/8 agonist 1 retains TLR7-agonistic activity with an EC50 of 20 nM.
S0078	1V209 (TLR7 agonist T7)	1V209 (T7, TLR7 agonist T7) is an agonist of Toll-like receptor 7 (TLR7) with anti-tumor effects. 1V209 can be used as vaccine adjuvants, enhances antigen specific humoral and cellular immune responses.
S0494	SM 324405	SM 324405 (compound 9e) is a potent and selective Toll-like receptor 7 (TLR7) agonist with EC50 of 50 nM.
S2952	SM-276001	SM-276001 is a potent and selective agonist of TLR7 that induces antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.
S2979	CU-T12-9	CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.
S7161	Motolimod (VTX-2337)	Motolimod (VTX-2337) is a selective and potent Toll-like receptor 8 (TLR8) agonist with EC50 of 100 nM, > 50-fold selectivity over TLR7. Phase 2.	Cell Rep, 2021, 35(7):109143 J Leukoc Biol, 2020, 1 J Pharm Biomed Anal, 2020, 179:112987
S7221	Vesatolimod (GS-9620)	Vesatolimod (GS-9620) is a potent and selective orally active small molecule agonist of Toll-like receptor 7.	PLoS Pathog, 2022, 18(3):e1010354 J Pharm Biomed Anal, 2020, 179:112987 Stem Cell Res Ther, 2019, 10(1):387
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.	Small, 2022, 18(4):e2103552 Adv Mater, 2021, 33(51):e2104362 Pharmaceutics, 2021, 13(3)365
S8428^New	FSL-1	FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection.
S9623	Telratolimod	Telratolimod (3M-052, MEDI9197) is an agonist of toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) with antitumor activity.
E3594^New	Radix tetrastigme Extract	Radix Tetrastigme Extract is extracted from Tetrastigma hemsleyanum, which can modulate TLR4/COX-2/NF-κB signaling pathway.
E3625^New	Cnidii Fructus Extract	Cnidii Fructus Extract is extracted from Cnidii Fructus, the dry ripe fruit of Cnidium monnieri (L.)Cuss.. Chinese herbal medicine Cnidii Fructus has an outstanding effect on chronic lumbar pain and impotence, also has been used against osteoporosis with high frequency.
E1134^New	ABR-238901	ABR-238901 is a novel S100A8/A9 blocker that potently inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4).
E3193^New	Saponaria Officinalis Extract	Saponaria Officinalis Extract is extracted from Saponaria Officinalis, which reduces downstream inflammatory responses by disrupting the TLR4/MD2 complex and blocking MyD88-dependent inflammatory signaling.
S9937^New	CU-CPD107	CU-CPD107 is a selective, dual-activity small-molecule which demonstrated differential activity against the TLR8 agonists and ssRNA ligands. In the presence of R848, CU-CPD107 acts as a TLR8 signaling inhibitor (IC50=13.7 μM). In the presence of ssRNA, CU-CPD107 shows synergistic agonist activities, while CU-CPD107 alone is unable to influence TLR8 signaling.
E0639^New	TLR7/8 agonist 1 dihydrochloride	TLR7/8 agonist 1 dihydrochloride is a toll-like receptor TLR7/TLR8 dual-agonistic imidazoquinoline.TLR7/8 agonist 1 retains TLR7-agonistic activity with an EC50 of 20 nM.
S8428^New	FSL-1	FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection.
E3594^New	Radix tetrastigme Extract	Radix Tetrastigme Extract is extracted from Tetrastigma hemsleyanum, which can modulate TLR4/COX-2/NF-κB signaling pathway.
E3625^New	Cnidii Fructus Extract	Cnidii Fructus Extract is extracted from Cnidii Fructus, the dry ripe fruit of Cnidium monnieri (L.)Cuss.. Chinese herbal medicine Cnidii Fructus has an outstanding effect on chronic lumbar pain and impotence, also has been used against osteoporosis with high frequency.